Gene Expression Profiling of Inflammatory Breast Cancer
Gene Expression Profiling of Inflammatory Breast Cancer
复制标题
DOI：
10.1002/cncr.25165
复制
发表时间：
2010-06-01
期刊：
影响因子：
6.2
通讯作者：
Viens, Patrice
中科院分区：
文献类型：
--
作者：
Bertucci, Francois;Finetti, Pascal;Viens, Patrice
背景：炎症性乳腺癌(IBC)是一种罕见但侵袭性强的乳腺癌。尽管进行了多种治疗，但IBC患者的长期存活率仍然较低，仅为50%。直到最近，对IBC的研究还停留在分子水平上。自2004年以来，新的高通量分子图谱技术被应用于临床样本，目的是识别可能涉及疾病发展的基因或途径，这些基因或途径可能代表新的临床相关靶点。方法：作者对IBC临床样本进行了基因表达谱研究，并调查了未来可能解决的问题，以使“组学”方法在IBC中充分发挥其潜力。结果：从2004年12月开始，6个研究小组比较了IBC样本和非IBC样本的表达谱。样本系列很小(最大的研究是37个IBCs)和异质性(使用了不同的肿瘤选择标准和技术平台)。结果表明，IBC组织中信使RNA的表达谱是可行的，并证明了IBC在转录水平上的高度异质性，并且存在与非IBC相似的分子亚型，这些亚型更多的是基本的和ERBB2阳性的。监督分析表明，在不同的研究中，IBC和非IBC变量之间的基因表达水平存在差异，有时没有或非常细微的差异，到目前为止，报告的签名中没有基因重叠。目前还没有可靠地识别或验证可预测治疗反应或临床结果的信号。结论：由于IBC的高度异质性，未来的研究将必须包括更大系列的IBC样本，这些样本是用同质标准选择的。这需要紧急的国际合作。癌症2010年；116(11补充)：2783-93。(C)2070年美国癌症协会。
BACKGROUND: Inflammatory breast cancer (IBC) is a rare but aggressive form of breast cancer. Despite multimodality treatment, the long-term survival rate for patients with IBC has remained inferior at 50%. Until recently, IBC was understudied at the molecular level. Since 2004, new high-throughput molecular profiling technologies have been applied to clinical samples with the aim of identifying genes or pathways potentially involved in disease development that may represent new, clinically relevant targets. METHODS: The authors conducted gene expression profiling studies of IBC clinical samples and investigated issues that may be addressed in the future to allow the "omics" approach to reach its full potential in IBC. RESULTS: Starting in December 2004, 6 research groups compared the expression profiles of IBC samples and non-IBC samples. The series of samples were small (37 IBCs for the largest study) and heterogeneous (various tumor selection criteria and technologic platforms were used). The results indicated the feasibility of messenger RNA expression profiling from IBC biopsies, and they demonstrated the great transcriptional heterogeneity of IBC and the existence of molecular subtypes similar to non-IBC that more frequently were basal and positive for ERBB2. Supervised analyses demonstrated differences in gene expression levels between the IBC and non-IBC variable across studies with sometimes no or very subtle differences and, to date, no gene overlap across the reported signatures. No signature predictive of therapeutic response or clinical outcome has been reliably identified or validated. CONCLUSIONS: Because of the great heterogeneity of IBC, future studies will have to include larger series of IBC samples that are selected using homogeneous criteria. This calls for urgent international collaborations. Cancer 2010;116(11 suppl):2783-93. (C) 2070 American Cancer Society.